Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7048
Gene Symbol: TGFBR2
TGFBR2
CUI: C0015672
Disease: Fatigue
Fatigue
0.400 Biomarker CTD_human Clinical features in a family with an R460H mutation in transforming growth factor beta receptor 2 gene. 16885183

2006

Entrez Id: 7048
Gene Symbol: TGFBR2
TGFBR2
CUI: C0015672
Disease: Fatigue
Fatigue
0.400 Biomarker HPO

Entrez Id: 2056
Gene Symbol: EPO
EPO
CUI: C0015672
Disease: Fatigue
Fatigue
0.330 Biomarker BEFREE Erythropoietin and methylphenidate significantly reduced fatigue severity in patients with cancer and in recipients of hsct. 29719440

2018

Entrez Id: 2056
Gene Symbol: EPO
EPO
CUI: C0015672
Disease: Fatigue
Fatigue
0.330 Biomarker BEFREE Combined treatment with EPO and EA was well tolerated, and all 18 patients who suffered from fatigue prior to therapy recovered. 27271482

2017

Entrez Id: 2056
Gene Symbol: EPO
EPO
CUI: C0015672
Disease: Fatigue
Fatigue
0.330 Therapeutic CTD_human A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. 18695134

2008

Entrez Id: 2056
Gene Symbol: EPO
EPO
CUI: C0015672
Disease: Fatigue
Fatigue
0.330 Biomarker BEFREE Originally characterized as a growth factor for erythrocytes, erythropoietin (EPO) is used to treat anemia and fatigue in cancer patients receiving radiation therapy and chemotherapy. 15856028

2005

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0015672
Disease: Fatigue
Fatigue
0.310 Biomarker CTD_human Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. 8759893

1996

Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
CUI: C0015672
Disease: Fatigue
Fatigue
0.310 Biomarker BEFREE Side effects of IFNa (fatigue, anorexia, weight loss) were frequent, and 3 patients decided to drop out of the treatment. 7770930

1995

Entrez Id: 8797
Gene Symbol: TNFRSF10A
TNFRSF10A
CUI: C0015672
Disease: Fatigue
Fatigue
0.300 Biomarker CTD_human Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. 19652058

2009

Entrez Id: 210
Gene Symbol: ALAD
ALAD
CUI: C0015672
Disease: Fatigue
Fatigue
0.200 Biomarker RGD We also examined the activity of the enzyme ALA dehydratase (ALAD), which is the second enzyme in the heme biosynthetic pathway, and ALAD gene expression during the fatigue and its recovery sessions. 17204241

2007

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 Biomarker BEFREE Naturally occurring human mutations influence a wide range of CBG properties and point toward a role in hitherto unexplained chronic musculoskeletal pain and fatigue disorders as well as potentially affecting fertility outcomes including offspring gender. 27214312

2016

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 GeneticVariation BEFREE Corticosteroid-binding globulin (CBG; SERPIN A6) gene mutations are rare; only four mutations have been described, often in association with fatigue and chronic pain, albeit with incomplete penetrance. 22013108

2012

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 GeneticVariation BEFREE Rare kindreds with CBG mutations reducing CBG levels or altering binding affinity have been described, along with clinical manifestations encompassing fatigue, chronic pain, and hypotension. 21795453

2011

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 GeneticVariation BEFREE The mechanisms by which CBG mutations may cause fatigue are unknown. 19643166

2010

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 GeneticVariation LHGDN To the best of our knowledge, this case represents the first de novo mutation reported for corticosteroid-binding globulin deficiency, implicating a pathogenic role of variants of SERPINA6 in some cases of muscle fatigue. 17245537

2007

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 GeneticVariation BEFREE To the best of our knowledge, this case represents the first de novo mutation reported for corticosteroid-binding globulin deficiency, implicating a pathogenic role of variants of SERPINA6 in some cases of muscle fatigue. 17245537

2007

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 AlteredExpression BEFREE A mechanism for the effect of CBG mutations on fatigue is not readily apparent because free cortisol levels are normal, although we speculate that CBG may have an effect on cortisol-brain transport. 17547679

2007

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 GeneticVariation LHGDN Association between chronic fatigue syndrome and the corticosteroid-binding globulin gene ALA SER224 polymorphism. 15554358

2004

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 GeneticVariation BEFREE Although relative hypotension and fatigue have recently been associated with CBG deficiency in a family with two CBG mutations (null and Lyon), the two homozygous subjects in this kindred were both normotensive and only the proband presented with fatigue. 12780753

2003

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 Biomarker BEFREE As idiopathic fatigue disorders are associated with relatively low plasma cortisol, abnormalities of corticosteroid-binding globulin may be pathogenic. 11502797

2001

Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
CUI: C0015672
Disease: Fatigue
Fatigue
0.190 Biomarker HPO

Entrez Id: 213
Gene Symbol: ALB
ALB
CUI: C0015672
Disease: Fatigue
Fatigue
0.160 Biomarker BEFREE The aim of this study was to investigate the predictive factors of objective response rate (ORR) and progression-free survival (PFS), and the correlation of albumin-bilirubin (ALBI) grade with decreased appetite and fatigue in hepatocellular carcinoma patients treated with lenvatinib. 31760660

2020

Entrez Id: 213
Gene Symbol: ALB
ALB
CUI: C0015672
Disease: Fatigue
Fatigue
0.160 AlteredExpression BEFREE After adjustments of variables, female sex, younger age at diagnosis, and lower serum albumin level were independently associated with fatigue scores, while a longer follow-up period and lower serum albumin levels were associated with itch scores. 30135523

2018

Entrez Id: 213
Gene Symbol: ALB
ALB
CUI: C0015672
Disease: Fatigue
Fatigue
0.160 AlteredExpression BEFREE The improvement in pain and fatigue was supported by the ECOG performance status remaining stable with the highest score being equal to 2 throughout the study and a trend towards an improvement in GPS performance status and albumin levels. 30519091

2018

Entrez Id: 213
Gene Symbol: ALB
ALB
CUI: C0015672
Disease: Fatigue
Fatigue
0.160 GeneticVariation BEFREE We assessed fatigue using three fatigue scales-the Brief Fatigue Inventory (BFI), the Edmonton Symptom Assessment System (ESAS), and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30)-and determined their association with objective assessments, including handgrip strength, maximal inspiratory pressure, lean body mass, phase angle, and albumin. 28063860

2017